Executive Summary

The global medical technology (medtech) industry is entering a period of accelerated transformation. Structural forces spanning pricing policies, care delivery models, supply chain architecture, clinical pathways, and enabling technologies are redefining how companies compete and where growth is generated. Five trends stand out for 2026: Mainland China's evolving volume-based procurement (VBP) program, the continued migration of procedures to outpatient settings, intensifying global trade pressures on manufacturing strategy, the ripple effects of GLP-1 therapies, and the emergence of platform-based competition driven by robotics and digital workflows. Each trend carries significant commercial implications for multinational corporations, emerging players, investors, and healthcare systems worldwide.

Introduction

The medtech sector is not merely expanding; it is being restructured. Companies that achieve success in the coming era will be those that recognize the convergence of policy, economics, and technology. The forces described here are not isolated developments. They interact: VBP pricing pressure pushes innovation toward value-based care; outpatient migration demands new commercial capabilities; supply chain volatility forces manufacturing flexibility; GLP-1 therapies alter procedure volumes; and enabling technologies create new competitive ecosystems. This analysis decodes these trends and their strategic consequences, providing a framework for decision-makers navigating the 2026 landscape.

Business Context

The medtech market has historically been characterized by steady growth fueled by demographic demand, technological innovation, and expanding healthcare access. However, the industry now faces a more complex environment. Cost-containment policies, site-of-care transformation, geopolitical trade uncertainty, and technology convergence are eroding traditional growth models. The companies best positioned for the future are those that can adapt their portfolios, manufacturing footprints, and customer engagement strategies accordingly.

Main Analysis

1. Mainland China's VBP Expansion Reshapes Market Economics

Mainland China's national volume-based procurement program, initially designed to improve patient access and lower device costs, has evolved into a powerful market-structuring mechanism. The latest VBP rounds introduce more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational corporations, VBP is no longer a localized policy issue. The pricing benchmarks and volume expectations set in China are influencing negotiations and competitive positioning in other emerging markets, and even in developed economies where reference pricing is becoming more common.

Strategically, VBP is accelerating the rise of domestic Chinese competitors and forcing multinationals to reassess their product portfolios, market access strategies, and local partnerships. Companies that view China solely as a revenue opportunity may find their market share eroding. Those that align with the evolving policy direction, invest in local innovation, and adopt flexible pricing models will be better positioned to sustain participation in this strategically vital market.

2. Outpatient and ASC Settings Become Central to Procedure Strategy

The migration of procedures from hospital inpatient settings to outpatient and ambulatory surgical centers (ASCs) is accelerating. The U.S. Centers for Medicare & Medicaid Services (CMS) 2026 OPPS and ASC Payment System Final Rule expands the ASC Covered Procedure List and continues to phase out the inpatient-only list. This enables higher-acuity procedures, including cardiac ablation, to move into lower-cost settings when clinically appropriate.

For medtech manufacturers, this shift has profound implications. Commercial models must evolve to address the distinct economic priorities of ASCs, which emphasize efficiency, shorter recovery times, and lower overall costs. Product design will need to accommodate smaller footprints, ease of use, and compatibility with outpatient workflows. The trend also affects hospital purchasing patterns, as volumes migrate, and drives differentiation through value-based propositions that resonate with a broader array of care sites.

3. Trade and Supply Chain Pressures Reshape Manufacturing Strategy

Supply chain resilience has moved from operational concern to strategic imperative. Tariff exposure, geopolitical conflict, and fluctuating material costs are challenging longstanding assumptions about where and how devices are manufactured. In response, medtech companies are diversifying sourcing, rebalancing supplier concentrations, and investing in multi-region manufacturing footprints.

Scale is becoming an advantage. Larger manufacturers can leverage integration and technology investment to buffer against volatility, potentially widening their competitive lead over smaller peers. The geographic distribution of production, as well as the portfolio of products subject to tariffs, now influences cost structures and profit margins. Consequently, supply chain strategy is no longer a back-office function; it is a board-level determinant of competitiveness.

4. GLP-1 Therapies Alter Care Pathways and Procedure Demand

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists is reshaping the management of obesity and metabolic disease. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s have expanded treatment access and changed referral patterns. Certain bariatric procedures are experiencing sharper volume pressure, and downstream effects are emerging across diabetes care, sleep apnea, cardiovascular monitoring, and other device-intensive areas.

The GLP-1 effect is not uniform, but its trajectory is clear: it signals a broader shift in metabolic disease management toward pharmaceutical interventions that precede, complement, or defer surgery. Medtech companies in adjacent specialties must anticipate how patient pathways will evolve, identify new opportunities for device-assisted care, and reassess the long-term volume outlook for procedures that may be disrupted by pharmacotherapy.

5. Enabling Technologies Drive Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer peripheral to medtech procedures; they are central to an integrated ecosystem that supports clinical planning, surgical execution, and postoperative care. Companies are investing heavily in platform architectures that anchor entire service lines, deepen customer relationships, and generate data-driven value propositions.

The emergence of open-platform systems is expanding flexibility and creating new competitive dynamics. Providers increasingly expect interoperability and choice, rather than being locked into a single vendor. This trend rewards companies that can build robust ecosystems and partner effectively, while those relying on siloed, single-function devices risk commoditization. Platform-based competition is redefining how value is delivered and how customer loyalty is sustained.

Commercial Impact

These five trends will have broad commercial impact. For multinational medtech companies, China's VBP compels portfolio restructuring and local innovation. The ASC shift opens new customer segments but demands alterations in sales force structure, pricing, and education. Supply chain volatility requires capital investment and strategic sourcing, affecting cash flow and margins. GLP-1 therapies could soften demand for certain capital equipment or implants, while boosting other monitoring and diagnostic categories. Platform-based technologies create opportunities for recurring revenue models, data monetization, and stickier customer relationships.

Investors and analysts should watch how companies respond on earnings calls, through R&D allocations, and in merger and acquisition activity. The ability to articulate a clear strategy for navigating these trends will be a key differentiator in company valuations.

Strategic Insights

The coming years will reward strategic agility. Medtech firms need to approach these trends holistically. A portfolio strategy that considers product lines individually will miss the systemic nature of change. For example, a device used in bariatric surgery may need to be repositioned as part of a broader metabolic health solution that includes both surgical and pharmaceutical elements. Similarly, a company that sells into hospitals must prepare for a future where the same product may be used in an ASC or even in a home care setting.

Collaboration will become an important strategic lever. Partnerships with technology companies, data analytics firms, and even pharmaceutical companies can help medtech firms integrate GLP-1 impacts into planning, build open platforms, and navigate the regulatory and economic complexities of global markets. On the manufacturing front, companies should adopt scenario planning and invest in flexible production capabilities.

Another key insight is the growing importance of evidence-based value demonstration. Payers and providers are increasingly requiring proof that devices reduce overall healthcare costs, improve outcomes, or enhance patient experience. Companies that invest in real-world evidence and health economics studies will be better equipped to justify pricing in an era of VBP and value-based care.

Future Outlook

Looking toward the next three to ten years, these trends will intensify and interact. VBP-style pricing could expand beyond China to other markets, making global reference pricing a reality. Site-of-care migration will continue, with more complex procedures moving to outpatient settings and perhaps into home-based care, enabled by remote monitoring and digital health tools. Supply chains will become more regionally distributed and digitally transparent, with AI-driven predictive analytics mitigating disruptions.

The GLP-1 landscape will evolve as next-generation therapies enter the market, potentially expanding indications and influencing even more procedure volumes. Medtech companies should prepare for a future where pharmaceutical interventions and mechanical devices are complementary components of treatment pathways, and business models must reflect this integrated care paradigm.

Platform economics will dominate, with the most valuable companies controlling the data and integration points across care ecosystems. Artificial intelligence will play a central role in surgical planning, intraoperative guidance, and workflow optimization, elevating the importance of software and data analytics in device differentiation. As the medtech industry becomes more technology-intensive, the traditional boundaries between medical devices, information technology, and services will continue to blur.

Ultimately, the medtech companies that thrive in 2026 and beyond will be those that embrace strategic transformation, invest in resilience, and place value—both economic and clinical—at the heart of their corporate strategy.

Conclusion

The forces identified in this analysis—China's VBP expansion, the shift to outpatient care, supply chain pressures, GLP-1 therapies, and platform-based competition—are redefining the global medtech landscape. They are not isolated events but interconnected developments that require an integrated strategic response. Business leaders must assess their product portfolios, manufacturing footprints, commercial models, and technological investments through the lens of these trends. Those who do will be better positioned to navigate the market's complexity and capture growth in a rapidly evolving sector.